However, orforglipron: Provides double-digit weight loss Works without needles or refrigeration May improve long-term adherence compared with weekly injections This places it among the most promising oral GLP-1 options currently in late-stage development
Xenoestrogens: the emerging story of bisphenol A
Hauth JC, Clifton RG, Roberts JM, Spong CY, Myatt L, Leveno KJ, Pearson GD, Varner MW, Thorp JM, Mercer BM, et al: Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trial
A practical approach
These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
Nature 477 , 171178 (2011)
